Advances in emerging drugs for the treatment of neuroblastoma. (2nd January 2017)

• Record Type: Journal Article
• Authors: Berlanga, Pablo; Cañete, Adela; Castel, Victoria
• Is Part Of: Expert opinion on emerging drugs. Volume 22:Number 1(2017:Mar.)
• Page Start: 63
• Page End: 75
• Publication Date: 2017-01-02
• Subjects: Neuroblastoma -- drug development -- emerging drugs -- targeted therapies -- chemotherapy -- high-dose chemotherapy -- radiotherapy -- immunotherapy -- ALK inhibitors -- PI3K/AKT/mTOR inhibitors; Drugs -- Research -- Handbooks, manuals, etc; Drugs -- Design -- Periodicals; 615.1072
• DOI: 10.1080/14728214.2017.1294159
• Languages: English
• ISSNs: 1472-8214

Abstract

ABSTRACT: Introduction: Neuroblastoma is the most common solid extracranial tumor of childhood. Outcome for children with high-risk neuroblastoma remains suboptimal. More than half of children diagnosed with high-risk neuroblastoma either do not respond to conventional therapies or relapse after treatment with dismal prognosis. Areas covered: This paper presents a short review of the state of the art in the current treatment of high-risk neuroblastoma. An updated review of new targeted therapies in this group of patients is also presented. Expert opinion: In order to improve prognosis for high-risk patients there is an urgent need to better understand spatial and temporal heterogeneity and obtain new predictive preclinical models in neuroblastoma. Combination strategies with conventional chemotherapy and/or other targeted therapies may overcome current ALK inhibitors resistance. Improvement of international and transatlantic cooperation to speed clinical trials accrual is needed.